Drug developer Revive Therapeutics Ltd told investors that specialist Dr Yanlin Wang will become a scientific advisor to the firm on cannabinoid-based therapeutics, which target kidney diseases.
The biotech is investigating the potential of drugs and plant-based therapies, such as cannabinoids, that may be repurposed for new indications.
Wang is an associate professor of medicine and a director of basic research at the Selzman Institute for Kidney Health and Section of Nephrology of the Department of Medicine at Baylor College of Medicine.
He is also a Fellow of the American Society of Nephrology, as well as an active clinician.
Craig Leon, chief executive of Revive, said: “Dr. Wang has experience with a number of research kidney models that will help to advance developments to the clinic and he will be instrumental in assisting Revive’s initiatives in the product and clinical development of cannabinoid-based therapeutics for kidney diseases.”
Story by ProactiveInvestors